1 Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010;24:1743–56.
2 Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169–73.
3 Jalkh AE, Jabbour N, Avila MP, et al. Retinal pigment epithelium decompensation. I. clinical features and natural course. Ophthalmology 1984;91:1544–8.
4 Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013;58:103–26.
5 Klein ML, Van Buskirk EM, Friedman E, et al. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol 1974;91:247–50.
6 Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-Term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 2019;126:576–88.
7 Hosoda Y, Miyake M, Schellevis RL, et al. Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. Commun Biol 2019;2:468.
8 Miyake M, Ooto S, Yamashiro K, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 2015;5:16204.
9 Tsai D-C, Chen S-J, Huang C-C, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One 2013;8:e66858.
10 Rim TH, Kim HS, Kwak J, et al. Association of corticosteroid use with incidence of central serous chorioretinopathy in South Korea. JAMA Ophthalmol 2018;136:1164–9.
11 Hirose N, Ishimaru M, Morita K, et al. A review of studies using the Japanese national database of health insurance claims and specific health checkups. Annals of Clinical Epidemiology 2020;2:13–26.
12 Kido A, Tamura H, Ikeda HO, et al. Nationwide incidence of central retinal artery occlusion in Japan: an exploratory descriptive study using the National database of health insurance claims (2011-2015). BMJ Open 2020;10:e041104.
13 Sugihara T, Yasunaga H, Matsui H, et al. Regional clinical practice variation in urology: usage example of the open data of the National database of health insurance claims and specific health checkups of Japan. Int J Urol 2019;26:303–5.
14 Kato G. History of the secondary use of national database of health insurance claims and specific health checkups of Japan (NDB). Trans Jpn Soc Med Biol Eng 2017;55:143–50.
15 Matsuda S, Fujimori K. The claim database in Japan. Asian Pac J Dis Manag 2014;6:55–9.
16 Kubo S, Noda T, Myojin T. National database of health insurance claims and specific health checkups of Japan (NDB): outline and Patient-Matching technique. bioRxiv 2018:280008.
17 Okumura Y, Usami M, Okada T, et al. Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol Psychiatr Sci 2019;28:692–6.
18 Sie-Boen-Lian. The etiological agent of serous central chorioretinitis. Ophthalmologica 1964;148:263–70.
19 Ahmad OB, Boschi Pinto C, Lopez AD. Age standardization of rates: a new who standard. GPE Discussion Paper Series 2001;31:10–12.
20 Salehi M, Wenick AS, Law HA, et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 2015;12:Cd011841. doi:10.1002/14651858.CD011841.pub2
21 Lu HQ, Wang EQ, Zhang T, et al. Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis. Eye 2016;30:15–22. doi:10.1038/eye.2015.208
22 Kono S, Ikeda M, Ogata M. Salt and geographical mortality of gastric cancer and stroke in Japan. J Epidemiol Community Health 1983;37:43–6.
23 Hayama K, Sugai N, Tanaka S, et al. High-Incidence of C9 deficiency throughout Japan: there are no significant differences in incidence among eight areas of Japan. Int Arch Allergy Appl Immunol 1989;90:400–4.
24 Sakai R, Wang W, Yamaguchi N, et al. The impact of Japan’s 2004 postgraduate training program on intra-prefectural distribution of pediatricians in Japan. PLoS One 2013;8:e77045.
25 Conway MD, Noble JA, Peyman GA. Central serous chorioretinopathy in postmenopausal women receiving exogenous testosterone. Retin Cases Brief Rep 2017;11:95–9.
26 Matet A, Daruich A, Zola M, et al. Risk factors for recurrences of central serous chorioretinopathy. Retina 2018;38:1403–14.
27 Kim Y-K, Ryoo N-K, Woo SJ, et al. Choroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathy. Am J Ophthalmol 2015;160:72–84.
28 van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 2019;73:100770.
29 Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012;32:1829–37.
30 Sulzbacher F, Schütze C, Burgmüller M, et al. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol 2019;257:1581–90.
31 Wu J-S, Chen S-N. Optical coherence tomography angiography for diagnosis of choroidal neovascularization in chronic central serous chorioretinopathy after photodynamic therapy. Sci Rep 2019;9:9040.
32 Cassel GH, Brown GC, Annesley WH. Central serous chorioretinopathy: a seasonal variation? Br J Ophthalmol 1984;68:724–6.
33 Kida T, Kobayashi T, Sato T, et al. Seasonal variation in Japanese central serous chorioretinopathy. Ophthalmologica 2018;240:150–6.
34 Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res 2020;79:100865.
35 Hayashi S, Noda T, Kubo S, et al. Variation in fracture risk by season and weather: a comprehensive analysis across age and fracture site using a national database of health insurance claims in Japan. Bone 2019;120:512–8.
論文の公開元へ
